UnitedHealthcare HNS Coverage Update Prior Auth

Coverage Criteria

Implantable hypoglossal nerve stimulation — adults

Covered when ALL of the following are met

Adult hypoglossal nerve stimulation eligibility: Body Mass Index (BMI) ≤ 40 kg/m2; AND Apnea‑Hypopnea Index (AHI) ≥ 15 and ≤ 100 on attended polysomnography; AND Total central + mixed apneas < 25% of AHI; AND Absence of complete concentric collapse at the soft palate level; AND PAP therapy resulted in no therapeutic efficacy or patient refusal or intolerance; AND Device is used in accordance with FDA labeling/guidance

Implantable hypoglossal nerve stimulation — adolescents with Down syndrome

Covered when ALL of the following are met

Adolescent (Down syndrome) hypoglossal nerve stimulation eligibility: Diagnosis of severe OSA by polysomnography within 24 months with AHI ≥ 10 and RDI ≤ 50 events/hour; AND BMI < 95th percentile for age; AND Total central + mixed apneas < 25% of AHI; AND Contraindication to or persistent OSA after prior adenotonsillectomy; AND Confirmed failure or intolerance of PAP therapy despite attempts to improve compliance; AND No tracheostomy use during sleep; AND Absence of complete blockage or concentric collapse of the soft palate confirmed by medication‑induced sleep endoscopy (DISE); AND Individual and caregiver refusal of maxillomandibular osteotomy/advancement for nonconcentric palatal collapse; AND Device use in accordance with FDA guidance

Non-surgical oral appliance therapy

Covered when ALL of the following are met

Removable oral appliance therapy for OSA: Obstructive sleep apnea (OSA) documented by a sleep study (polysomnography or adequately performed home sleep apnea testing); AND Oral appliance prescribed and managed by qualified providers (medical diagnosis by a physician and fitting/management by a qualified dentist); AND Device is custom‑fabricated/titratable per specialty guidance (custom preferred over prefabricated); AND Follow‑up sleep testing is performed to confirm efficacy and to monitor for dental side effects

Evidence-based coverage considerations for alternative non-CPAP devices

Coverage decisions should reflect evidence strength; below are summarized patterns from the reviewed literature (NOT explicit authorization rules).

Positional therapy devices (vibratory trainers, NightBalance, SPT): Short‑term RCTs and observational studies show positional devices can reduce AHI and may improve adherence in selected patients with positional OSA, but CPAP produces greater AHI reduction and long‑term efficacy is uncertain.

Document positional dependency (supine‑predominant OSA), baseline AHI and follow‑up outcomes when used; evidence quality low to moderate.

Nasal dilators (internal and external): Systematic reviews and meta‑analyses generally show no significant improvement in AHI with external nasal dilators; internal dilators may show minimal benefit in select studies.

Not recommended as primary therapy for OSA based on current evidence.

Intranasal expiratory resistance valves (EPAP): Randomized trials show EPAP devices can reduce AHI versus sham in some patients with mild‑to‑severe OSA and may improve symptoms, but EPAP is inferior to CPAP for moderate‑to‑severe OSA and long‑term responder selection is unclear.

Coverage considerations and sequencing

Coverage considerations based on guideline recommendations and study populations:

First‑line therapy: CPAP/APAP is recommended as the initial therapy for adult OSA per multiple specialty guidelines.

Applies to adults; CPAP preference noted in AASM, ACP and related guidance.

Oral appliance therapy (custom, titratable device fitted by a qualified dentist) is appropriate for patients with mild‑to‑moderate OSA or for those intolerant of CPAP; follow‑up sleep testing is recommended to confirm efficacy.

AADSM/AASM guidance; evidence quality low to moderate.

Hypoglossal nerve stimulation (HNS): HNS may be considered for selected patients with moderate‑to‑severe OSA who have failed or are intolerant of CPAP; evidence demonstrates AHI and symptom improvements but is limited by study design and sample size in many reports.

STAR trial and systematic reviews report substantial AHI reductions; consider device‑specific eligibility and anatomic exclusions.

Transvenous Phrenic Nerve Stimulation (remedē) — Evidence Summary

Considered investigational/insufficient evidence for broad clinical benefit pending further research; limited circumstances may show improvement in CSA metrics and QOL.

Key evidence points for remedē transvenous phrenic nerve stimulation (TPNS): Randomized pivotal trial (Costanzo et al.) demonstrated 51% of treatment patients achieved ≥50% AHI reduction at 6 months versus 11% of controls; longer‑term follow‑up reports in subsets show sustained AHI/CAI and PROM improvements up to 5 years, but overall evidence is limited by small samples, risk of bias, and incomplete long‑term data.

Safety: device‑related serious adverse events occurred but were relatively infrequent; additional randomized comparative and longitudinal outcome data are needed before broad coverage.

Hypoglossal Nerve Stimulation (HNS) in Down Syndrome Adolescents

Small prospective case series and cohorts report substantial AHI reductions and QOL improvements in selected adolescents with Down syndrome and severe OSA who are CPAP‑intolerant and without circumferential palatal collapse.

Typical inclusion and observed responses in HNS studies for Down syndrome adolescents: Patients generally aged ~10–21 years with pre‑op PSG within 6 months, DISE to exclude circumferential palatal collapse when performed, device activation ~1 month after implant; responders often defined as ≥50% AHI reduction with reported responder rates and median AHI reductions varying across small series.responder = ≥50% reduction in AHI

Laser-Assisted Uvulopalatoplasty (LAUP)

Evidence is insufficient to support LAUP as effective OSA therapy; systematic reviews and randomized trials show low success and potential for worsening disease.

LAUP evidence summary: Meta‑analysis (Camacho et al.) reported ~23% success (≥50% AHI reduction and AHI <20) and 8% cure rate, with 44% of patients showing worsening AHI; randomized trials show minimal or inconsistent benefit for OSA outcomes.

Lingual Suspension / Tongue Base Suspension

Suture‑based and device‑based tongue suspension techniques have mixed results; combined procedures often show higher success but evidence is low quality and device failure concerns exist.

Lingual/tongue suspension evidence summary: Systematic reviews and case series report variable success rates for tongue suspension alone (~36.6%) and higher success when combined with UPPP (≈61–74% depending on technique); device‑specific failures (e.g., tissue‑anchor/barb fractures) have been reported and long‑term comparative data are lacking.

Hyoid Myotomy / Hyomandibular Suspension (AirLift/Encore System)

Limited evidence; small case series report substantial AHI reductions when combined with UPPP but overall evidence insufficient.

Hyoid myotomy/hyomandibular suspension evidence summary: Small series report mean AHI reductions when adjustable hyomandibular suspension is performed with modified UPPP (examples: mean AHI reduction from ~42.0 to ~10.8); complications reported include bleeding, seroma, infection; studies limited by small size and lack of controls.Surgical success often defined as postoperative AHI <20 and ≥50% reduction

Conditional coverage with documentation and selection criteria

Coverage is conditional and generally limited due to insufficient high‑quality evidence; when considered, authorization should require ALL of the following:

Common preconditions for conditional coverage: Documented OSA with baseline PSG/HSAT demonstrating AHI consistent with intended indication; AND Documented intolerance or failure of CPAP and/or oral appliance therapy where applicable; AND Procedure‑specific selection criteria including anatomic site of obstruction (DISE or other assessment) and device candidacy; AND Informed consent documenting risks and alternative treatments and plan for objective follow‑up (AHI and PROMs).Many studies report success criteria of postoperative AHI <20 and ≥50% reduction

Procedures with limited evidence: Lingual suspension, hyoid myotomy/suspension, palatal implants, radiofrequency ablation, TORS, and DOME have limited or low‑quality evidence; authorization decisions should be individualized and require strong clinical justification and objective outcome documentation.

Eligibility for surgical and implantable therapies

Procedures and implantable devices are recommended primarily for patients who meet one or more of the following guideline‑supported conditions:

Prerequisite therapies: Failure or intolerance of first‑line noninvasive therapy (e.g., CPAP, BiPAP, oral appliance therapy, weight loss where appropriate) or therapies are inappropriate for the patient.

Supported by AAO‑HNS, AASM, ERS, VA/DoD guidance

Inspire upper airway stimulation (UAS) eligibility general considerations: Patient meets device‑specific AHI/BMI range per FDA labeling, has failed or cannot tolerate PAP, and does not have complete concentric collapse at the soft palate.

Document AHI and BMI per device labeling and DISE findings where required.

Surgical considerations: Maxillomandibular advancement (MMA) may be indicated for severe OSA when PAP is not tolerated or effective; multilevel surgery may be considered for appropriately selected patients; UPPP may be considered in patients unable to use PAP though evidence is low quality.

DOME (Distraction Osteogenesis for Maxillary Expansion)

Distraction osteogenesis for maxillary expansion (DOME):

DOME evidence and coverage implication: Available literature consists primarily of small retrospective case series without randomized controlled trials and lacking long‑term outcomes; evidence is insufficient to conclude effectiveness for adult OSA and routine coverage is not supported absent stronger data.

Implantable hypoglossal nerve stimulation — Adults (revised)

Covered when ALL of the following are met:

Adult implantable hypoglossal nerve stimulation (updated): 1) FDA‑approved implantable hypoglossal nerve stimulation device; AND 2) PAP therapy resulted in no therapeutic efficacy or there was patient refusal or intolerance; AND 3) AHI ≥ 15 and ≤ 100 on attended polysomnography; AND Used in accordance with FDA guidance.AHI ≥ 15 and ≤ 100

This revision removed prior requirements for failed adequate trials of CPAP and oral appliance therapy and added explicit PAP efficacy/refusal/intolerance requirement.

Implantable hypoglossal nerve stimulation — Adolescents with Down syndrome (revised)

Covered when ALL of the following are met:

Adolescent (10–18) Down syndrome HNS (updated): 1) Age 10–18 years with Down syndrome; AND 2) FDA‑approved device as applicable; AND 3) Confirmed failure or intolerance of PAP therapy despite attempts to improve compliance; AND 4) Other device‑ and FDA‑specific requirements (e.g., DISE exclusion of circumferential palatal collapse) as applicable.ages 10–18

Revision added requirement for confirmed failure/intolerance of PAP despite compliance efforts and removed prior documentation requirement for CPAP refusal.

Implantable hypoglossal nerve stimulation — adults (duplicate)

Covered when ALL of the following are met

Adult hypoglossal nerve stimulation eligibility (duplicate entry): Implantable hypoglossal nerve stimulation with an FDA‑approved device in an adult patient with moderate to severe OSA: PAP therapy resulted in no therapeutic efficacy or patient refusal or intolerance; AND AHI ≥ 15 and ≤ 100 on attended polysomnography.AHI ≥ 15 and ≤ 100

Implantable hypoglossal nerve stimulation — adolescents with Down syndrome (duplicate)

Covered when ALL of the following are met

Adolescent Down syndrome HNS eligibility (duplicate): Implantable hypoglossal nerve stimulation with an FDA‑approved device in adolescents aged 10–18 years with Down syndrome: confirmed failure or intolerance of PAP therapy despite attempts to improve compliance; and other device/FDA‑specified criteria as applicable.ages 10–18

The policy identifies a set of devices and procedures that are considered unproven and not medically necessary due to insufficient evidence of efficacy. These include devices for treating positional OSA (e.g., vibratory trainers, NightBalance), nasal dilator devices, intranasal expiratory resistance valves (e.g., Bongo Rx), removable oral appliances for Central Sleep Apnea (CSA), prefabricated (ready‑made) oral appliances, non‑surgical electrical muscular training (daytime intraoral NMES), mandibular vertical repositioning devices (e.g., Slow Wave), morning repositioning devices, epigenetic appliances (e.g., Homeoblock, DNA), and Advanced Lightweight Functional (ALF) appliances. The policy revision also updated this list to explicitly add ALF as an item considered unproven/not medically necessary.

Removable oral appliances and other intraoral devices that mechanically reposition the jaw are not supported for Central Sleep Apnea (CSA). The policy states no relevant evidence was identified to support the use of removable oral appliances for CSA, and therefore requests for such devices for CSA are considered unsupported and may be denied.

The policy lists mandibular vertical repositioning devices (for example, Slow Wave) and several tongue‑base suspension systems as lacking quality evidence and therefore unproven. Case series evaluating adjustable lingual suspension devices identified device/tissue‑anchor failure (e.g., radiographic anchor/barb fractures) that limit clinical use. The Advance System (adjustable tongue base suspension) and other similar device systems are noted as not FDA‑approved for U.S. marketing and are considered unproven without robust comparative evidence.

Laser‑Assisted Uvulopalatoplasty (LAUP) is not routinely recommended. Meta‑analysis and guideline summaries report low success rates and a meaningful risk of worsening OSA (for example, pooled analyses showed only a minority met success/cure criteria and up to 44% had worsening AHI). The policy therefore cautions that LAUP should be performed with caution or avoided as a routine OSA treatment.

Several surgical procedures and devices are described as having insufficient comparative evidence or known device failure concerns and are therefore unproven or not medically necessary when proposed as routine treatments. Examples include lingual suspension/tongue fixation (device anchor failures reported), stand‑alone uvulectomy, palatal implants, radiofrequency ablation of the soft palate/tongue, transoral robotic surgery (TORS), and distraction osteogenesis for maxillary expansion (DOME). Authorization for these approaches requires strong, procedure‑specific justification and objective pre/post testing when considered.

NICE interventional guidance and related reviews conclude that evidence for soft‑palate (palatal) implants is inadequate to support routine use in OSA. NICE specifically advises that soft‑palate implants should not be used for treating OSA given the limited and low‑quality evidence.

The policy notes that certain implantable tongue‑base suspension and hypoglossal stimulation systems (for example, the Advance System and Aura6000) are not FDA‑approved for U.S. marketing. In addition, the policy clarifies that routine dental services related to oral appliance management are generally excluded under the medical plan (see dental codes D9947/D9948/D9949).

The policy clarifies that claims for routine dental services associated with oral appliance provision (for example, codes D9947, D9948, D9949) are generally excluded from coverage under the medical plan and may be denied if submitted to the medical benefit. Durable medical equipment codes for custom/prefabricated oral appliances remain the appropriate mechanism when medical coverage is indicated and criteria are met.

Implantable neurostimulation devices for Central Sleep Apnea (for example, the remedē System) are considered unproven or not medically necessary in some contexts because current evidence is limited. Technology assessments and meta‑analyses report reductions in AHI/CAI and some quality‑of‑life improvements, but the overall evidence base is small, of low to very‑low quality in places, and lacks long‑term comparative data demonstrating clinical outcome benefits beyond physiological measures.

The policy concludes that nasal dilators and mandibular vertical repositioning devices are not supported by quality evidence for meaningful OSA benefit and are therefore considered not medically necessary when proposed as primary OSA treatments. Systematic reviews show little to no consistent AHI improvement for external/inferior‑quality studies of nasal dilators, and no quality evidence was identified for vertical‑opening mandibular devices.

The policy lists numerous therapies for which no quality evidence was identified and which are therefore considered unproven/not medically necessary. These include mandibular vertical repositioning devices, morning repositioning devices, epigenetic appliances, Advanced Lightweight Functional (ALF) appliances, certain prefabricated oral appliances, and other novel or proprietary intraoral systems. The policy emphasizes that absence of reliable evidence precludes routine coverage.

While some studies of the remedē transvenous phrenic nerve stimulation system report improvements in physiologic metrics (AHI/CAI) and patient‑reported outcomes in selected cohorts and up to five years of follow‑up in subsets, the policy states that evidence remains insufficient in some contexts. Additional randomized comparative trials and longer‑term outcome data are required before broad coverage for clinical outcome benefits can be assumed.

Stand‑alone uvulectomy and palatal implants lack sufficient high‑quality evidence to demonstrate effectiveness as OSA therapies. The policy highlights limited case series and short‑term studies for procedures such as uvulectomy, palatal implants, radiofrequency ablation, and DOME, and therefore these procedures are considered unproven for routine use in adults absent robust comparative data.

Consistent with professional guidance, the policy indicates that LAUP is not routinely recommended for treatment of OSA. Meta‑analytic data and AASM guidance show LAUP rarely normalizes AHI and may worsen OSA in a sizable proportion of patients; therefore LAUP should not be used as a standard OSA therapy.

The policy was revised to update the list of items considered unproven and not medically necessary. The updated list explicitly includes additional intraoral appliance categories such as Advanced Lightweight Functional (ALF) appliances and reiterates previously identified items like positional devices, nasal dilators, prefabricated appliances, and certain surgical procedures.

As part of the revision, ALF (Advanced Lightweight Functional) appliances were added to the policy's list of unproven and not medically necessary devices due to lack of quality evidence supporting efficacy for OSA.

Coding

Surgical and implanted device CPT codesCPT

21142	Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft.
21199	Osteotomy, mandible, segmental; with genioglossus advancement.
21206	Osteotomy, maxilla, segmental (e.g., Wassmund or Schuchard).
21685	Hyoid myotomy and suspension.
33276	Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed.
33277	Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure).
33278	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s).
33279	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only.
33280	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only.
33281	Repositioning of phrenic nerve stimulator transvenous lead(s).

1–10 of 26

1/3

HCPCS and miscellaneous device codesHCPCS

A7049	Expiratory positive airway pressure intranasal resistance valve.
E0485	Oral device/appliance used to reduce upper airway collapsibility, adjustable or nonadjustable, prefabricated, includes fitting and adjustment.
E0486	Oral device/appliance used to reduce upper airway collapsibility, adjustable or nonadjustable, custom fabricated, includes fitting and adjustment.
E0492	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application.
E0493	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply.
E0530	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type.
E1399	Durable medical equipment, miscellaneous.
K1027	Oral device/appliance used to reduce upper airway collapsibility, without fixed mechanical hinge, custom fabricated, includes fitting and adjustment.
L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.

1–10 of 13

1/2

No explicit codes listed in this document sectionmixed

No codes listed

Codes referencedmixed

not specified

No explicit CPT/HCPCS/ICD-10 codes listed in this document segment

Codes not specified in this sectionmixed

No codes listed

FDA device approvals / 510(k) / PMA / de novo identifiersmixed

K180608	510(k) - Lunoa System (NightBalance BV)
K180619	510(k) - Bongo intranasal appliance (InnoMed Healthscience)
K982717	510(k) - Somnoplasty System (Olympus/Gyrus ENT)
K030108	510(k) - Coblation technology (ArthroCare ENT)
DEN200018	de novo - eXciteOSA tongue stimulation device
K191320	510(k) - Slow Wave DS8
P160039	PMA - remedē System (phrenic nerve stimulator) for central sleep apnea
K981677	510(k) - AIRvance / Repose Tongue Suspension System (Medtronic ENT)
K040417	510(k) - Pillar System (palatal implants) (Medtronic ENT)
P130008	PMA - Inspire Upper Airway Stimulation system (Inspire Medical Systems Inc.)

1–10 of 12

1/2

Dental codes generally excludedmixedNot Covered

D9947	Dental service code referenced as generally excluded under the medical plan
D9948	Dental service code referenced as generally excluded under the medical plan
D9949	Dental service code referenced as generally excluded under the medical plan

Dental services generally excludedmixedNot Covered

D9947	dental service (noted as generally excluded under medical plan)
D9948	dental service (noted as generally excluded under medical plan)
D9949	dental service (noted as generally excluded under medical plan)

AHI and BMI thresholds for hypoglossal nerve stimulation (adult and adolescent criteria)

Adult hypoglossal nerve stimulation — BMIBody Mass Index (BMI) ≤ 40 kg/m2

Adult hypoglossal nerve stimulation — AHIApnea‑Hypopnea Index (AHI) ≥ 15 and ≤ 100 on attended polysomnography

Adult hypoglossal nerve stimulation — central/mixed apneasTotal central + mixed apneas < 25% of total AHI

Adult hypoglossal nerve stimulation — anatomic exclusionAbsence of complete concentric collapse at the soft palate level

Adolescent (Down syndrome) hypoglossal stimulation — AHI/RDIPolysomnogram within 24 months with AHI ≥ 10 and RDI ≤ 50 events/hour

Provider Actions and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization required for implantable devices and many surgical OSA interventions. Submit a prior authorization request before scheduling implantation or surgery to confirm medical necessity and coverage.

Applies to implantable hypoglossal nerve stimulation (UAS) devices and implantable neurostimulators for CSA (e.g., remedē/TPNS)
Also recommended for multilevel or device-based surgical procedures (e.g., TORS, genioglossus advancement)

Note

Device therapy authorization support

Authorization support and coordination may be required for device-based therapy. Work with the payer’s medical management team and device manufacturer representatives to ensure required pre-authorization testing and documentation are submitted.

Pre-authorization requests should include operative plan, device model, and FDA indication confirmation
Coordinate with manufacturer for device-specific documentation and programming/activation plans

Background

Obstructive Sleep Apnea (OSA) is characterized by recurrent upper airway obstruction during sleep that leads to apneas and hypopneas and is associated with excessive daytime sleepiness and cardiometabolic consequences. OSA severity is typically classified using the Apnea‑Hypopnea Index (AHI), with thresholds commonly used to guide treatment decisions (for example, AHI ≥ 15 often denotes at least moderate disease). The policy addresses both non‑surgical and surgical treatment options and distinguishes OSA from Central Sleep Apnea (CSA), where respiratory drive is impaired and different therapies may apply.

Definitions

Apnea / Obstructive vs Central vs Mixed

Apnea definitionCessation of airflow lasting at least 10 seconds (≥90% decrease in airflow excursions)

Obstructive vs Central vs MixedObstructive apnea: continued/increased inspiratory effort; Central apnea: absent inspiratory effort; Mixed: initial absent effort then resumption

Hypopnea definition≥10 seconds with ≥30% reduction in airflow plus ≥3% oxygen desaturation or associated arousal

Apnea Hypopnea Index (AHI)

AHI definitionNumber of apneas plus hypopneas per hour of sleep (events/hour)

Severity categoriesMild: AHI 5–<15; Moderate: 15–30; Severe: >30 events/hour

Revision History

2024-12-01policy_revisionLatest

Revised coverage criteria: for adult implantable hypoglossal nerve stimulation added requirement that PAP therapy resulted in no therapeutic efficacy or patient refusal or intolerance; removed prior requirement for failure of adequate trials of CPAP and oral appliance therapy; lowered attended polysomnography AHI threshold from ≥20 to ≥15 (AHI ≥15 and ≤100). Also updated adolescent (ages 10–18 with Down syndrome) criteria to require confirmed failure or intolerance of PAP despite attempts to improve compliance and removed prior documentation requirement when patient refused CPAP.

Administrative: this policy version (CS116KY.15) notes the archiving of the previous policy version CS116KY.14 in the Policy History/Revision Information section dated 12/01/2024 and documents multiple material changes to coverage criteria and the list of unproven items.

OpenPayer

Obstructive and Central Sleep Apnea Treatment (for Kentucky Only)

Coverage Criteria

Coding

Provider Actions and Prior Authorization

Background

Definitions

Revision History